Hepatorenal Syndrome: A Review of Pathophysiology and Current Treatment Options.
作者信息
Erly Brian, Carey William D, Kapoor Baljendra, McKinney J Mark, Tam Mathew, Wang Weiping
机构信息
Case Western Reserve University School of Medicine, Cleveland, Ohio.
Department of Gastroenterology, Cleveland Clinic, Cleveland, Ohio.
出版信息
Semin Intervent Radiol. 2015 Dec;32(4):445-54. doi: 10.1055/s-0035-1564794.
Abstract
摘要
相似文献
1
Hepatorenal Syndrome: A Review of Pathophysiology and Current Treatment Options.
Semin Intervent Radiol. 2015 Dec;32(4):445-54. doi: 10.1055/s-0035-1564794.
2
Hepatorenal syndrome: pathophysiology and evidence-based management update.
Rom J Intern Med. 2021 Aug 26;59(3):227-261. doi: 10.2478/rjim-2021-0006. Print 2021 Sep 1.
3
Hepatorenal syndrome: pathophysiology, diagnosis, and management.
BMJ. 2020 Sep 14;370:m2687. doi: 10.1136/bmj.m2687.
4
Hepatorenal syndrome: a decade later.
J Assoc Physicians India. 2014 Aug;62(8):696-702.
5
Hepatorenal syndrome: aetiology, diagnosis, and treatment.
Gastroenterol Res Pract. 2015;2015:207012. doi: 10.1155/2015/207012. Epub 2015 Jan 12.
6
Review article: pharmacological treatment of the hepatorenal syndrome in cirrhotic patients.
Aliment Pharmacol Ther. 2000 May;14(5):515-21. doi: 10.1046/j.1365-2036.2000.00740.x.
7
Hepatorenal syndrome: a comprehensive overview for the critical care nurse.
Crit Care Nurs Clin North Am. 2010 Sep;22(3):351-68. doi: 10.1016/j.ccell.2010.03.001.
8
Impact of hepatorenal syndrome and liver transplantation.
Curr Opin Organ Transplant. 2011 Jun;16(3):301-5. doi: 10.1097/MOT.0b013e328346576c.
9
[Research advances in pathophysiology and diagnosis and treatment of hepatorenal syndrome].
Zhonghua Gan Zang Bing Za Zhi. 2017 Apr 20;25(4):246-248. doi: 10.3760/cma.j.issn.1007-3418.2017.04.002.
10
[Hepatorenal syndrome - pathophysiology, diagnosis and treatment].
Vnitr Lek. 2015 Jul-Aug;61(7-8):649-54.
引用本文的文献
1
Understanding acute kidney injury in cirrhosis: Current perspective.
World J Hepatol. 2025 May 27;17(5):104724. doi: 10.4254/wjh.v17.i5.104724.
2
Mitigating renal dysfunction in liver cirrhosis: Therapeutic role of ferrous sulphate, folic acid, and its co-administration.
Toxicol Rep. 2025 Apr 9;14:102026. doi: 10.1016/j.toxrep.2025.102026. eCollection 2025 Jun.
3
Review on Kidney-Liver Crosstalk: Pathophysiology of Their Disorders.
Cell J. 2024 Feb 1;26(2):98-111. doi: 10.22074/cellj.2023.2007757.1376.
4
Treatment-Related Cost Analysis of Terlipressin for Adults with Hepatorenal Syndrome with Rapid Reduction in Kidney Function.
Adv Ther. 2023 Dec;40(12):5432-5446. doi: 10.1007/s12325-023-02674-z. Epub 2023 Oct 9.
5
A Systematic Review of the Emerging Treatment for Hepatorenal Syndrome With a Principal Focus on Terlipressin: A Recent FDA-Approved Drug.
Cureus. 2023 Jul 24;15(7):e42367. doi: 10.7759/cureus.42367. eCollection 2023 Jul.
6
The Efficacy of Carvedilol in Comparison to Propranolol in Reducing the Hepatic Venous Pressure Gradient and Decreasing the Risk of Variceal Bleeding in Adult Cirrhotic Patients: A Systematic Review.
Cureus. 2023 Aug 10;15(8):e43253. doi: 10.7759/cureus.43253. eCollection 2023 Aug.
7
COVID-19 and hepatorenal syndrome.
World J Gastroenterol. 2022 Oct 21;28(39):5666-5678. doi: 10.3748/wjg.v28.i39.5666.
8
Management of Liver Decompensation in Advanced Liver Disease (Renal Impairment, Liver Failure, Adrenal Insufficiency, Cardiopulmonary Complications).
Clin Drug Investig. 2022 Jun;42(Suppl 1):15-23. doi: 10.1007/s40261-022-01149-3. Epub 2022 May 6.
9
Hepatorenal syndrome: a Nationwide Trend Analysis from 2008 to 2018.
Ann Med. 2021 Dec;53(1):2018-2024. doi: 10.1080/07853890.2021.1998595.
10
Liver Kidney Crosstalk: Hepatorenal Syndrome.
World J Hepatol. 2021 Sep 27;13(9):1058-1068. doi: 10.4254/wjh.v13.i9.1058.
本文引用的文献
1
New consensus definition of acute kidney injury accurately predicts 30-day mortality in patients with cirrhosis and infection.
Gastroenterology. 2013 Dec;145(6):1280-8.e1. doi: 10.1053/j.gastro.2013.08.051. Epub 2013 Aug 30.
2
Relative adrenal insufficiency in decompensated cirrhosis: Relationship to short-term risk of severe sepsis, hepatorenal syndrome, and death.
Hepatology. 2013 Nov;58(5):1757-65. doi: 10.1002/hep.26535. Epub 2013 Aug 7.
3
Cirrhotic ascites review: Pathophysiology, diagnosis and management.
World J Hepatol. 2013 May 27;5(5):251-63. doi: 10.4254/wjh.v5.i5.251.
4
Underestimation of liver-related mortality in the United States.
Gastroenterology. 2013 Aug;145(2):375-82.e1-2. doi: 10.1053/j.gastro.2013.04.005. Epub 2013 Apr 9.
5
Successful treatment of severe hepatorenal syndrome with living donor liver transplantation.
Hepatogastroenterology. 2012 Oct;59(119):2305-6. doi: 10.5754/hge10791.
6
Cardiac and renal effects of a transjugular intrahepatic portosystemic shunt in cirrhosis.
Eur J Gastroenterol Hepatol. 2013 May;25(5):523-30. doi: 10.1097/MEG.0b013e32835d09fe.
7
Percutaneous placement and management of the Denver shunt for portal hypertensive ascites.
AJR Am J Roentgenol. 2012 Oct;199(4):W449-53. doi: 10.2214/AJR.12.9203.
8
The transjugular intrahepatic portosystemic shunt: an update.
AJR Am J Roentgenol. 2012 Oct;199(4):746-55. doi: 10.2214/AJR.12.9101.
9
Clinical outcomes of patients with hepatorenal syndrome after living donor liver transplantation.
Liver Transpl. 2012 Oct;18(10):1237-44. doi: 10.1002/lt.23493.
10
Urinary neutrophil gelatinase-associated lipocalin predicts mortality and identifies acute kidney injury in cirrhosis.
Dig Dis Sci. 2012 Sep;57(9):2362-70. doi: 10.1007/s10620-012-2180-x. Epub 2012 May 6.
Zotero 插件